All
Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases
December 11th 2024Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101
December 6th 2024The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.